Numerous murine models of heart failure (HF) have been described, many of which develop progressive deterioration of cardiac function. We have recently demonstrated that several of these can be "rescued" or prevented by transgenic cardiac expression of a peptide inhibitor of the beta-adrenergic receptor kinase (betaARKct). To uncover genomic changes associated with cardiomyopathy and/or its phenotypic rescue by the betaARKct, oligonucleotide microarray analysis of left ventricular (LV) gene expression was performed in a total of 53 samples, including 12 each of Normal, HF, and Rescue. Multiple statistical analyses demonstrated significant differences between all groups and further demonstrated that betaARKct Rescue returned gene expression ...
A mouse model of hypertrophic cardiomyopathy (HCM) was created by expression of a cardiac alpha-myos...
Cardiac hypertrophy and heart failure remain leading causes of death in the United States. Many stud...
The medical treatment of chronic heart failure has undergone a dramatic transition in the past decad...
Heart failure is accompanied by severely impaired beta-adrenergic receptor (betaAR) function, which ...
BACKGROUND: Heart failure is characterized by abnormalities in beta-adrenergic receptor (betaAR) sig...
Genetic factors are known to modulate cardiac susceptibility to ventricular hypertrophy and failure....
Background—Although -adrenergic receptor (AR) blockade therapy is beneficial in the treatment of hea...
Heart failure (HF) accounts for 1 in 9 deaths in the United States and is the leading cause of hospi...
GRKs critically regulate betaAR signaling via receptor phosphorylation and the triggering of desensi...
We aimed to understand the genetic control of cardiac remodeling using an isoproterenol-induced hear...
Heart failure (HF) is the leading cause of death worldwide. It is a complex disease involving multip...
Using a transgenic mouse model of myocardial-targeted overexpression of the wild-type alpha1B adrene...
The genetics of heart failure is complex. In familial cases of cardiomyopathy, where mutations of la...
Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant disease characterized by left ve...
A mouse model of hypertrophic cardiomyopathy (HCM) was created by expression of a cardiac alpha-myos...
Cardiac hypertrophy and heart failure remain leading causes of death in the United States. Many stud...
The medical treatment of chronic heart failure has undergone a dramatic transition in the past decad...
Heart failure is accompanied by severely impaired beta-adrenergic receptor (betaAR) function, which ...
BACKGROUND: Heart failure is characterized by abnormalities in beta-adrenergic receptor (betaAR) sig...
Genetic factors are known to modulate cardiac susceptibility to ventricular hypertrophy and failure....
Background—Although -adrenergic receptor (AR) blockade therapy is beneficial in the treatment of hea...
Heart failure (HF) accounts for 1 in 9 deaths in the United States and is the leading cause of hospi...
GRKs critically regulate betaAR signaling via receptor phosphorylation and the triggering of desensi...
We aimed to understand the genetic control of cardiac remodeling using an isoproterenol-induced hear...
Heart failure (HF) is the leading cause of death worldwide. It is a complex disease involving multip...
Using a transgenic mouse model of myocardial-targeted overexpression of the wild-type alpha1B adrene...
The genetics of heart failure is complex. In familial cases of cardiomyopathy, where mutations of la...
Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant disease characterized by left ve...
A mouse model of hypertrophic cardiomyopathy (HCM) was created by expression of a cardiac alpha-myos...
Cardiac hypertrophy and heart failure remain leading causes of death in the United States. Many stud...
The medical treatment of chronic heart failure has undergone a dramatic transition in the past decad...